TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00929409
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
Study: NCT00929409
Drug: Ferrous sulfate tablets
Normalized name: Ferrous Sulfate Tablets
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
Study: NCT03558477
Drug: Nexium
Normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nexium
Study: NCT01315145
Drug: Epidural Steroid Injection
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of epidural steroids into the lumbar spine
Study: NCT02112526
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02793544
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).~An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD.
Study: NCT01462565
Drug: current marketed FLOLAN (epoprostenol sodium)
Normalized name: epoprostenol Injection [Flolan]
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous intravenous infusion
Study: NCT01462565
Drug: new thermo stable formulation of epoprostenol sodium
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous intravenous infusion
Study: NCT02793544
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.~Additional G-CSF may be administered as warranted.
Study: NCT02793544
Drug: Pre-HCT Mesna on Days -6 and -5
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight.
Study: NCT02793544
Drug: Pre-HCT Mesna on Days -2 and -1
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight.
Study: NCT02793544
Drug: Pre-HCT Mesna on Days -5 and -4
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight.
Study: NCT02793544
Drug: Post-HCT Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.~Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight.
Study: NCT01848730
Drug: CNV2197944
Normalized name: CNV2197944
DrugBank: CNV-2197944 (DB15229)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01545804
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
Study: NCT03583697
Drug: BMN 111
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 15 μg/kg/day and/or 30 μg/kg/day of BMN 111 daily, subject to adjustment per protocol
Study: NCT04253262
Drug: Rucaparib
Normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rucaparib (PO twice daily continuous)
Study: NCT05140096
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modify as Participants will receive a single oral dose of 100 mg (1 X 100 mg capsule) acalabrutinib either on Day 1 of Period 1 (Treatment A) and Day 1 of Period 2 (Treatment B) or Day 5 of Period 2 (Treatment C).
Study: NCT05140096
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 400 mg fluconazole (2 × 200 mg tablets) on Day 1 Period 2 (Treatment B).
Study: NCT05140096
Drug: Isavuconazole
Normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive oral dose of 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) three times daily on Day 1 and 200 mg isavuconazole (2 × 186 mg of isavuconazonium sulfate capsules) once daily on Days 2 to 5 in Period 2 (Treatment C).
Study: NCT04253262
Drug: Copanlisib
Normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copanlisib (IV day 1, 8, 15; 28 day cycle)
Study: NCT03931863
Drug: Ondansetron 4mg
Normalized name: ONDANSETRON 4MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
Study: NCT03931863
Drug: Ondansetron 8mg
Normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
Study: NCT01688518
Drug: Heated Lidocaine/Tetracaine Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01688518
Drug: 5% Lidocaine Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03572972
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment for NVAF patients
Study: NCT03572972
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for NVAF patients
Study: NCT03572972
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment for NVAF patients
Study: NCT03572972
Drug: warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for NVAF patients
Study: NCT02450591
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01817530
Drug: Elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral coated tablet
Study: NCT00001880
Drug: Cyclosporin
Normalized name: Cyclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin beginning day -4 and intravenous Methotrexate on days +1, +3, and +6 will be given
Study: NCT00824720
Drug: High Dose Device
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inserted for 14 days
Study: NCT00797108
Drug: sulopenem and PF-03709270
Normalized name: PF-05089771
DrugBank: Sulopenem (DB15284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day
Study: NCT00797108
Drug: Sulopenem and PF-03709270
Normalized name: PF-05089771
DrugBank: Sulopenem (DB15284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day
Study: NCT00797108
Drug: Ceftriaxone and amoxicillin/clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
Study: NCT01270750
Drug: BOSENTAN
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.
Study: NCT00904020
Drug: Lidoderm
Normalized name: Lidoderm
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
Study: NCT03770923
Drug: Rupatadine
Normalized name: Rupatadine
DrugBank: Rupatadine (DB11614)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rupatadine 10 mg daily
Study: NCT00824720
Drug: Low Dose Device
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: inserted for 14 days
Study: NCT03770923
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast 10 mg daily
Study: NCT00721409
Drug: PD 0332991
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
Study: NCT00721409
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg/d tablets orally on a continuous regimen
Study: NCT00254761
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01968798
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg enteric-coated aspirin, taken daily
Study: NCT01024738
Drug: Fluoride
Normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush half mouth twice daily for four days.
Study: NCT01024738
Drug: Triclosan, fluoride
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush twice daily
Study: NCT01024738
Drug: Chlorhexidine Gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rinse mouth twice a day
Study: NCT01910766
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: no more details
Study: NCT01910766
Drug: clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02497781
Drug: Ceftazidime -avibactam
Normalized name: avibactam / ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
Study: NCT02497781
Drug: Cefepime
Normalized name: Cefepime
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
Study: NCT00121381
Drug: Pimecrolimus plus topical corticosteroid (TCS)
Normalized name: pimecrolimus Topical Cream
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily
Study: NCT00121381
Drug: Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
Normalized name: pimecrolimus Topical Cream
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice daily administration
Study: NCT00004075
Drug: tanespimycin
Normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03147196
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03147196
Drug: Raloxifene Hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02752776
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
Study: NCT02138500
Drug: PF-06372865
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
Study: NCT02138500
Drug: PF-06372865
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
Study: NCT02467400
Drug: Atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: beta blocker
Study: NCT02467400
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: beta blocker
Study: NCT02224391
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via transdermal patch
Study: NCT02467400
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: beta blocker
Study: NCT01517074
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival injection
Study: NCT00404274
Drug: Casopitant (GW679769) oral tablets
Normalized name: maropitant Oral Tablet
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant will be available in the dose strength of 20,30 or 50 mg
Study: NCT02318147
Drug: The traditional treatment
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the traditional treatments according to associated guidelines
Study: NCT03502083
Drug: GLP-1 (7-36)Amide
Normalized name: (Gly2)GLP-2
DrugBank: GLP-1 (7-36) amide (DB19258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00404274
Drug: Warfarin oral tablets
Normalized name: warfarin Oral Tablet
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin will be available in the dose strength of 5 mg
Study: NCT04879420
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide dispensing claim is used as the reference group.
Study: NCT04879420
Drug: Risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate dispensing claim is used as the exposure group.
Study: NCT00690105
Drug: tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ointment
Study: NCT00690105
Drug: fluticasone 0.005 %
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ointment
Study: NCT02809404
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02975336
Drug: M2951
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 52 weeks.
Study: NCT02975336
Drug: M2951
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 75 mg of M2951 orally QD for 52 weeks.
Study: NCT02975336
Drug: M2951
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 50 mg of M2951 orally twice daily (BID) for 52 weeks.
Study: NCT02975336
Drug: M2951
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who had received Placebo or M2951 (25 mg QD, 75 mg QD or 50 mg BID) during DBPC period were switched to receive 50 mg M2951 orally BID in LTE period for 104 weeks.
Study: NCT02600949
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Applied topically
Study: NCT00421096
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.
Study: NCT00421096
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration
Study: NCT03305055
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Information included in arm descriptions
Study: NCT00866684
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment arm Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day
Study: NCT00866684
Drug: Mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
Study: NCT00866684
Drug: Ciclosporin
Normalized name: Ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Control arm Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
Study: NCT00866684
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
Study: NCT03274596
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02173223
Drug: Rho-Kinase Inhibitor
Normalized name: VEGFR 2 Kinase inhibitor I
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00241085
Drug: valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00874107
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
Study: NCT00874107
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
Study: NCT03186495
Drug: Somapacitan
Normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan
Study: NCT03302650
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.
Study: NCT01694264
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
Study: NCT01545635
Drug: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10\<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min~Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT \>90sec and FIBTEM A10\>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min~FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.~Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min
Study: NCT03198013
Drug: BMS-791826
Normalized name: BMS-791826
DrugBank: BMS-791826 (DB15023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04195906
Drug: Experimatenl SNF472 (Open-label)
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
Study: NCT02008318
Drug: Galunisertib
Normalized name: Galunisertib
DrugBank: Galunisertib (DB11911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally